
    
      Cohorts of 8 patients are entered sequentially into 1 of 6 1592U89 dosing regimens. All
      patients receive 12 weeks of monotherapy during the initial 12-week treatment phase.

      On completion of the treatment phase, patients are offered continuation therapy with 1592U89
      for a minimum of 12 weeks.
    
  